2025
BCL2 inhibition for multiple myeloma and AL amyloidosis
Cani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025, 206: 1285-1296. PMID: 40090369, DOI: 10.1111/bjh.20046.Peer-Reviewed Original ResearchMultiple myelomaAL amyloidosisBCL2 inhibitorsLight-chain (ALTreatment landscape of MMPlasma cell disorderMalignant blood disordersDevelopment of novel treatmentsBCL2 inhibitionTreatment landscapeDose optimizationCell disordersPatient selectionClinical studiesBlood disordersNovel treatmentAmyloidosisBCL2Light chainMyelomaToxicity concernsPatientsInhibitorsDrugTreatment
2024
A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.Peer-Reviewed Original ResearchPlasma cell disorderStandard armInfluenza vaccineMyeloma patientsIntensive armDaratumumab exposureRandomized Controlled TrialsMultiple myelomaFlu seasonCell disordersHistory of severe allergic reactionsStandard-dose influenza vaccinesTreat analysisRisk of influenza-like illnessT-cell engagersSeasonal influenza vaccineHigh dose vaccineHigh dose injectionsInfluenza-like illnessProportion of patientsFlu vaccinationVaccine preventable illnessYears of ageSevere allergic reactionsStatistically significant difference
2019
Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience
Paul Y, Aguirre L, Basher F, Miao F, Koru-Sengul T, Hoffman J. Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience. Blood 2019, 134: 3131. DOI: 10.1182/blood-2019-127247.Peer-Reviewed Original ResearchIncidence of significant infectionIncidence of hypogammaglobulinemiaIgG patientsIgG levelsMultiple myelomaSignificant infectionMonoclonal antibodiesPlasma cellsPolyclonal immunoglobulinsPatients treated with daratumumabAutologous stem cell transplantationHigh-risk cytogeneticsResponse to daratumumabTreated with daratumumabTreated with IVIGPlasma cell disorderStem cell transplantationImpaired humoral immunitySingle institution experiencePlasma cell diseaseBaseline IgG levelsRetrospective chart reviewUnivariate logistic regression modelIncidence of pre-Incidence of infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply